^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    becotarug (JMT101)

    i
    Other names: JMT101
    Company:
    CSPC Pharma
    Drug class:
    EGFR inhibitor
    Related drugs:
    3ms
    SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC (clinicaltrials.gov)
    P2, N=430, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd. | N=250 --> 430 | Initiation date: May 2025 --> Aug 2025 | Trial primary completion date: Sep 2027 --> Dec 2027
    Enrollment change • Trial initiation date • Trial primary completion date
    |
    becotarug (JMT101) • Enshuxing (enlonstobart)
    4ms
    The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=252, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P3 trial
    |
    Stivarga (regorafenib) • irinotecan • becotarug (JMT101)
    6ms
    SYS6002 Plus JMT101 and Enlonstobart Injection as First-Line Treatment for HNSCC (clinicaltrials.gov)
    P2, N=250, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2 trial
    |
    becotarug (JMT101) • Enshuxing (enlonstobart)
    9ms
    JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P2 trial
    |
    EGFR expression
    |
    gemcitabine • capecitabine • becotarug (JMT101) • Duoenda (mitoxantrone liposomal)
    12ms
    A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations (clinicaltrials.gov)
    P3, N=516, Recruiting, Shanghai JMT-Bio Inc.
    New P3 trial • Combination therapy • Metastases
    |
    Tagrisso (osimertinib) • becotarug (JMT101)
    over1year
    JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations (clinicaltrials.gov)
    P2, N=161, Active, not recruiting, Shanghai JMT-Bio Inc.
    New P2 trial
    |
    Tagrisso (osimertinib) • becotarug (JMT101)
    over1year
    JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations (clinicaltrials.gov)
    P3, N=398, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P3 trial • Combination therapy • EGFR exon 20 • Metastases
    |
    cisplatin • Tagrisso (osimertinib) • pemetrexed • becotarug (JMT101)
    over1year
    Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=534, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P2/3 trial
    |
    docetaxel • becotarug (JMT101)
    2years
    A Study of JMT101 in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=102, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P2 trial • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF wild-type
    |
    Stivarga (regorafenib) • irinotecan • becotarug (JMT101)
    over2years
    Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer. (PubMed, Nat Commun)
    Intracranial disease control rate is 87.5%. Confirmed intracranial objective response rate is 25%.
    P1 data • Journal • EGFR exon 20
    |
    EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • becotarug (JMT101)
    4years
    Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=155, Not yet recruiting, Shanghai JMT-Bio Inc.
    Clinical • New P2 trial • EGFR exon 20
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • becotarug (JMT101)
    over4years
    [VIRTUAL] JMT101 Combined With Afatinib or Osimertinib in Patients (pts) With NSCLC With EGFR Exon 20 Insertion Mutations (IASLC-WCLC 2021)
    The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.
    Clinical • EGFR exon 20
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib) • becotarug (JMT101)